IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
04 11월 2023 - 1:00AM
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage
biopharmaceutical company focused on innovative gamma-delta T cell
therapies, today presented new positive preclinical data from its
induced pluripotent stem cell (iPSC) gamma-delta T cell platform at
the Society for Immunotherapy of Cancer’s (SITC) 38th Annual
Meeting (Abstract #: 637 in Exhibit Halls A and B1). The data
represents a significant advance in the development of the INB-500
iPSC program towards the development of allogeneic gamma-delta T
cell therapies.
“Our deep understanding of gamma-delta T cell
biology allows for significant ex vivo expansion capabilities,”
said William Ho, Co-founder and CEO. “We have successfully
developed and utilized a robust serum and feeder-free process for
generating iPSC derived gamma-delta T cells, representing an
important step towards developing a truly allogeneic
‘off-the-shelf’ gamma-delta T cell source for therapeutic
development.”
The presented data underscores the platform’s
ability to reprogram donor cells into iPSCs, expand them, and guide
their differentiation into gamma-delta T cells through IN8bio’s
proprietary process, which can be scaled for full GMP
manufacturing. Notably, the platform enables the differentiation
into both Vd1+ and Vd2+ cell subtypes using cell-type specific
processes. The iPSC-derived gamma-delta T cells underwent
comprehensive characterization, encompassing morphological
analysis, cell surface markers and functional assessment via tumor
cell killing assays. Key findings include:
-
iVd1+ gamma-delta T cells expressed the cell markers expected of
innate gamma-delta T cells, including a strong capacity for
cytokine release, indicating that the cells possess an effector
phenotype.
-
To date, hundreds of millions of iVd1+ gamma-delta T cells have
been produced from single iPSC clones at a low passage number.
-
The cells demonstrated robust cytotoxic activity across a variety
of cancer cell lines, including ovarian, glioblastoma (GBM), acute
myeloid leukemia (AML) and chronic myeloid leukemia (CML) cell
lines, potentially providing an allogeneic platform for a broad
range of cancers.
-
Cryopreservation did not impact the cells with the Vd1+ gamma-delta
T cells showing comparable cytotoxicity to fresh cells, which
allows them to be expanded and banked for potential on-demand
clinical use.
“High concentrations of gamma-delta T cells in
both peripheral blood and in solid tumor infiltrates are associated
with improved survival outcomes in both hematopoietic and solid
cancers,” said Lawrence Lamb, PhD, Co-founder and Chief Scientific
Officer. “iPSC-derived gamma-delta cells could address existing
challenges, including donor sourcing and limitations of sufficient
cell numbers to sustain a therapeutic effect particularly in solid
tumors. iPSCs, with their nearly unlimited self-renewal capacity,
multi-lineage differentiation potential, and relative ease of
generic engineering offer the possibility of therapeutic cell
production for patients across a wide range of cancers.”
About IN8bioIN8bio is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of gamma-delta T cell product candidates for
solid and liquid tumors. Gamma-delta T cells are a specialized
population of T cells that possess unique properties, including the
ability to differentiate between healthy and diseased tissue.
IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and
genetically modified approaches to develop cell therapies, designed
to effectively identify and eradicate tumor cells.
IN8bio has initiated a Phase 2 trial of INB-400 in glioblastoma
(GBM) at multiple centers across the United States and has two
ongoing Phase 1 trials in solid and hematological tumors, including
INB-200 for GBM and INB-100 for patients with hematologic
malignancies undergoing transplantation. IN8bio also has a broad
portfolio of preclinical programs focused on addressing other
hematological and solid tumor cancers. For more information about
IN8bio and its programs, please visit www.IN8bio.com.
Forward Looking StatementsThis
press release may contain forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements may be identified by words
such as “aims,” “anticipates,” “believes,” “could,” “estimates,”
“expects,” “forecasts,” “goal,” “intends,” “may,” “plans,”
“possible,” “potential,” “seeks,” “will” and variations of these
words or similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these words. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the development and continued progress and success of our
preclinical and clinical trials and programs and product
candidates; the timing of initiation, progress (including as to
enrollment) and scope of clinical trials, including for INB-100,
INB-200 and INB-400; the success of gamma delta T cells as a
treatment option for patients with both solid and hematological
cancers; IN8bio’s ability to develop an ‘off-the-shelf’ gamma-delta
T cell source for therapeutic development; and IN8bio’s ability to
achieve anticipated milestones, including expected data readouts
from its trials, enrollment of additional patients in its clinical
trials, advancement of clinical development plans and to develop
new preclinical programs. IN8bio may not actually achieve the
plans, intentions or expectations disclosed in these
forward-looking statements, and you should not place undue reliance
on these forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations
disclosed in these forward-looking statements as a result of
various factors, including: risks to site initiation, clinical
trial commencement, patient enrollment and follow-up, as well as
IN8bio’s ability to meet anticipated deadlines and milestones;
uncertainties inherent in the initiation and completion of
preclinical studies and clinical trials and clinical development of
IN8bio’s product candidates; the risk that IN8bio may not realize
the intended benefits of its DeltEx platform; availability and
timing of results from preclinical studies and clinical trials;
whether the outcomes of preclinical studies will be predictive of
clinical trial results; whether initial or interim results from a
clinical trial will be predictive of the final results of the trial
or the results of future trials; the risk that trials and studies
may be delayed and may not have satisfactory outcomes; potential
adverse effects arising from the testing or use of IN8bio’s product
candidates; expectations for regulatory approvals to conduct trials
or to market products; IN8bio’s reliance on third parties,
including licensors and clinical research organizations; and other
important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements.
These and other factors are described in greater detail in the
section entitled “Risk Factors” in our Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission (SEC) on
August 10, 2023, as well as in other filings IN8bio may make with
the SEC in the future. Any forward-looking statements contained in
this press release speak only as of the date hereof, and IN8bio
expressly disclaims any obligation to update any forward-looking
statements contained herein, whether because of any new
information, future events, changed circumstances or otherwise,
except as otherwise required by law.
Company Contact:IN8bio, Inc.Patrick McCall+ 1
646.600.6GDT (6438)info@IN8bio.com
Investors & Media Contact: Argot
PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
IN8bio (NASDAQ:INAB)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024